Trial reportBMC complementary medicine and therapies2025
The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic factors and anthropometric indices in women with prediabetes: a study protocol for a double-blind randomized controlled trial.
Trial report in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrediabetes is a public health problem, and its prevalence is increasing around the world. Providing an effective strategy to prevent the progression of prediabetes and, consequently, type-2 diabetes mellitus (T2DM) could be useful for global health. Research suggests that vitamin D might contribute to decreasing the risk of developing and progressing T2DM. Moreover, Omentin-1 Val109Asp polymorphism is also reported to be associated with insulin resistance. Therefore, the primary aim of this trial is to investigate the interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic factors and anthropometric indices in women with prediabetes. METHODS/
designIn this double-blind randomized controlled trial, prediabetic women (n = 204) aged 18–65 years that will be recognized based on FBS: 100–125 mg/dL or HbA1c: 5.7-6.4% will be invited to participate in this study. After obtaining informed consent, all participants’ blood samples will be achieved to determine the Omentin-1 polymorphism (Val109Asp) genotypes. Then the women will be randomized to the intervention (n = 24) or placebo (n = 24) groups (1:1) in each genotype of Omentin-1 polymorphism. In total, 144 women will be allocated to receive vitamin D (50000 IU) or a placebo (1:1) every two weeks for 12 weeks. Supplements will be provided to the participants at the beginning of the study and the end of each month and data will be collected at the baseline and after 12 weeks. Primary outcome measures are fasting glucose, insulin serum, and serum lipid profile levels, and secondary outcome measures include anthropometric parameters and dietary intakes. DISCUSSION: The present trial will provide more required clinical evidence on the effects of vitamin D supplementation on glycemic control and insulin resistance by considering Omentin-1 polymorphism genetic variation in prediabetic patients, which is relevant for preventing T2DM.
trial registrationIRCT20100408003664N26.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.